Multiple Sclerosis and Related Disorders 37 (2020) 101576

Efficacy of Satralizumab As Monotherapy in Pre-Specified Subgroups of Sakurastar, a Double-Blind Placebo-Controlled Phase 3 Clinical Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Jeffrey L. Bennett [1], Benjamin Greenberg [2], Anthony Traboulsee [3], Lech Szczechowski [4], Edward Fox [5], Svitlana Shkrobot [6], Takashi Yamamura [7], Yusuke Terada [8], Yuichi Kawata [8], Pádraig Wright [9,10]

[1] *University of Colorado School of Medicine, Aurora, United States*
[2] *University of Texas Southwestern Medical Center, Dallas, United States*
[3] *University of British Columbia, Vancouver, Canada*
[4] *Silesian Centre of Neurology, Katowice, Poland*
[5] *Central Texas Neurology Consultants, Round Rock, United States*
[6] *Ternopil State Medical University, Ternopil, Ukraine*
[7] *National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan*
[8] *Chugai Pharmaceutical Co., Ltd, Tokyo, Japan*
[9] *Chugai Pharma Europe Ltd., London, United Kingdom*
[10] *F. Hoffmann-La Roche Ltd, Basel, Switzerland*

Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in the immune pathology of neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). Satralizumab, a humanised recycling monoclonal antibody that binds to the IL-6 receptor, reduced risk of relapse in patients with NMO or NMOSD as add-on therapy in the SAkuraSky study (NCT02028884) and monotherapy in the SAkuraStar study (NCT02073279).

SAkuraStar is a randomised, double-blind, Phase 3 clinical trial comparing satralizumab monotherapy with placebo. 95 patients with NMO or NMOSD, with ≥1 documented relapse in the year prior to screening, were randomised to satralizumab (120 mg s.c.) or placebo. The primary endpoint was time to first protocol-defined relapse (PDR). Pre-specified subgroup analyses assessed treatment response by AQP4-IgG serostatus, prior therapy, and relapse history. Between-group hazard ratios (HRs) were based on Cox proportional hazards models.

Overall, satralizumab reduced risk of PDR by 55% vs placebo (n=95; HR 0.45; 95% confidence interval [CI] 0.23–0.89; p=0.018). There was a 74% reduction in PDR risk with satralizumab vs placebo in AQP4-IgG-seropositive patients (n=64; HR 0.26; 95% CI 0.11–0.63). In AQP4-IgG-seronegative patients, the HR was 1.19 (n=31; 95% CI 0.30–4.78). The proportions of AQP4-IgG-seropositive patients who were relapse-free at Weeks 48 and 96 were 82.9% and 76.5% on satralizumab, and 55.4% and 41.1% on placebo, respectively. In AQP4-IgG-seronegative patients, proportions were 63.3% and 63.3% on satralizumab, and 77.8% and 77.8% on placebo, respectively. In patients previously treated with B-cell depleting therapy, the HR for PDR was 0.72 (n=12; 95% CI 0.12–4.30) with satralizumab vs placebo. In patients on prior immunosuppressant or other NMO/NMOSD therapies, this HR was 0.42 (n=83; 95% CI 0.20–0.87). Patients with >1 relapse in the year prior to screening had a HR for PDR of 0.42 with satralizumab vs placebo (n=84; 95% CI 0.21–0.85); those with one relapse during screening had no change in PDR risk (n=11; HR: 1.00, 95% CI 0.09–11.02).

Satralizumab was effective in reducing risk of PDR in patients with NMO or NMOSD, particularly in AQP4-IgG-seropositive patients. The study was not powered for subgroup analyses; therefore, results should be interpreted with caution.

doi: 10.1016/j.msard.2019.11.051

Multiple Sclerosis and Related Disorders 37 (2020) 101577

Cladribine Tablets Are a Cost-Effective and Cost-Saving Treatment Strategy for High Disease Activity Relapsing Multiple Sclerosis Patients in Iran

Nayyereh Ayati [1], Lora Fleifel [2], Shahdak Sharifi [2], Mohammad Ali Sahraian [3], Shekoufeh Nikfar [1]

[1] *Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Science, Tehran, Iran*
[2] *Merck Serono Middle East FZ-Ltd, an affiliate of Merck KGaA, Darmstadt, Germany, Dubai, United Arab Emirates*
[3] *MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran*

Cladribine tablets, hypothesized to act as an immune reconstitution therapy, are the first oral treatment for high disease activity relapsing multiple sclerosis (HDA-RMS). This study was conducted to assess the cost-effectiveness of cladribine tablets in comparison to natalizumab in HDA-RMS patients and also its budget impact in Iranian setting.

Cost-utility analysis (CUA): A Markov cohort model, with 21 expanded disability status scale (EDSS)-based health states was developed to compare cladribine tablets to natalizumab in a 5-year time horizon, from a societal perspective, in the context of Iran. Demographic and utility data were extracted from the CLARITY trial. Annual relapse rate and confirmed disability progression were extracted from a network meta-analysis, due to a lack of head-to-head trials. Mortality covariant such as age, sex and health states were also included. Effectiveness was assessed using quality adjusted life years (QALYs). Costs, which were identified through previous studies and expert opinion, were measured in Iranian Rial rates and converted to 2019 USD. Discount rates were 3.5% and 7.2% for QALY and costs, respectively. Probabilistic and deterministic sensitivity analyses (P/DSA) were conducted to assess robustness of the model.

Budget impact analysis (BIA): Markov-based static BIA was designed to compare total budgetary cost of two scenarios, with and without cladribine tablets, used in second-line treatment of RMS in a 10-year horizon. The Model was populated with the 2018 local MS pharmaceuticals usage data and included all available comparators (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod and natalizumab). Key cost inputs included drug acquisition, administration and monitoring costs.

CUA: Cladribine tablets was superior to natalizumab and was associated with cost savings of 6.607 USD and increased QALY of 0.003 per patient, over a 5-year time horizon. Drug acquisition was the major cost component (92% in both arms). Results were robust in DSA and PSA (57.5% probability of cost-effectiveness at a willingness-to-pay threshold of 2,709 USD).

BIA: Considering a cohort of 35,667 patients, inclusion of cladribine tablets as a second-line RMS treatment will yield −0.33% savings in budget (7,856,019 USD), over a 10-year horizon.

Results indicated that use of cladribine tablets in HDA-RMS is a cost-effective and also cost-saving strategy in Iran.

doi: 10.1016/j.msard.2019.11.052

Multiple Sclerosis and Related Disorders 37 (2020) 101578

Efficacy of Satralizumab (SA237) As Add-on Therapy in Pre-Specified Additional Analyses of Sakurasky, a Double-Blind Placebo-Controlled Phase 3 Study in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)

Takashi Yamamura [1], Ingo Kleiter [2], Kazuo Fujihara [3], Jacqueline Palace [4], Benjamin Greenberg [5], Beata Zakrzewska-Pniewska [6], Francesco Patti [7], Albert Saiz [8], Masayuki Haramura [9], Yusuke Terada [9,10]